{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:08:44Z","timestamp":1790352524518,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["381280"],"award-info":[{"award-number":["381280"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006315","name":"Reumafonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12969-019-0321-x","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T15:00:10Z","timestamp":1557154810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review"],"prefix":"10.1186","volume":"17","author":[{"name":"on behalf of the UCAN CAN-DU Health Economics Working Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6405-6789","authenticated-orcid":false,"given":"Michelle M. A.","family":"Kip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza","family":"Grazziotin Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinka","family":"Twilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J.","family":"Vastert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost F.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Wulffraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rae S. M.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne M.","family":"Benseler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"IJzerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"issue":"7","key":"321_CR1","first-page":"1520","volume":"29","author":"PJ Manners","year":"2002","unstructured":"Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol. 2002;29(7):1520\u201330.","journal-title":"J Rheumatol"},{"key":"321_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1546-0096-8-20","volume":"8","author":"LN Moorthy","year":"2010","unstructured":"Moorthy LN, Peterson MG, Hassett AL, Lehman TJ. Burden of childhood-onset arthritis. Pediatr Rheumatol Online J. 2010;8:20.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"9563","key":"321_CR3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767\u201378.","journal-title":"Lancet"},{"issue":"3","key":"321_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/acr.21801","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold S, Ward TM, Wallace CA. Disease activity and fatigue in juvenile idiopathic arthritis. Arthritis Care Res. 2013;65(3):391\u20137.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"321_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12969-016-0125-1","volume":"14","author":"W Armbrust","year":"2016","unstructured":"Armbrust W, Lelieveld OH, Tuinstra J, Wulffraat NM, Bos GJ, Cappon J, et al. Fatigue in patients with juvenile idiopathic arthritis: relationship to perceived health, physical health, self-efficacy, and participation. Pediatr Rheumatol Online J. 2016;14(1):65.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"3","key":"321_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00393-005-0652-5","volume":"64","author":"E Muller-Godeffroy","year":"2005","unstructured":"Muller-Godeffroy E, Lehmann H, Kuster RM, Thyen U. Quality of life and psychosocial adaptation in children and adolescents with juvenile idiopathic arthritis and reactive arthritis. Z Rheumatol. 2005;64(3):177\u201387.","journal-title":"Z Rheumatol"},{"issue":"2","key":"321_CR7","first-page":"142","volume":"23","author":"MS Mullick","year":"2005","unstructured":"Mullick MS, Nahar JS, Haq SA. Psychiatric morbidity, stressors, impact, and burden in juvenile idiopathic arthritis. J Health Popul Nutr. 2005;23(2):142\u20139.","journal-title":"J Health Popul Nutr"},{"key":"321_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2431-13-2","volume":"13","author":"I Bouaddi","year":"2013","unstructured":"Bouaddi I, Rostom S, El Badri D, Hassani A, Chkirate B, Amine B, et al. Impact of juvenile idiopathic arthritis on schooling. BMC Pediatr. 2013;13:2.","journal-title":"BMC Pediatr"},{"issue":"Suppl 1","key":"321_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10198-016-0786-1","volume":"17","author":"A Kuhlmann","year":"2016","unstructured":"Kuhlmann A, Schmidt T, Treskova M, Lopez-Bastida J, Linertova R, Oliva-Moreno J, et al. Social\/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. Eur J Health Econ. 2016;17(Suppl 1):79\u201387.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"321_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465\u201382.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"321_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40272-013-0023-7","volume":"15","author":"FH Prince","year":"2013","unstructured":"Prince FH, van Suijlekom-Smit LW. Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked. Paediatr Drugs. 2013;15(4):271\u201380.","journal-title":"Paediatr Drugs"},{"issue":"2","key":"321_CR12","first-page":"366","volume":"25","author":"B Flato","year":"1998","unstructured":"Flato B, Aasland A, Vinje O, Forre O. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol. 1998;25(2):366\u201375.","journal-title":"J Rheumatol"},{"issue":"1","key":"321_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12969-017-0172-2","volume":"15","author":"J Schlichtiger","year":"2017","unstructured":"Schlichtiger J, Haas JP, Barth S, Bisdorff B, Hager L, Michels H, et al. Education and employment in patients with juvenile idiopathic arthritis - a standardized comparison to the German general population. Pediatr Rheumatol Online J. 2017;15(1):45.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"321_CR14","doi-asserted-by":"publisher","first-page":"e0153267","DOI":"10.1371\/journal.pone.0153267","volume":"11","author":"S Barth","year":"2016","unstructured":"Barth S, Haas JP, Schlichtiger J, Molz J, Bisdorff B, Michels H, et al. Long-term health-related quality of life in German patients with juvenile idiopathic arthritis in comparison to German general population. PLoS One. 2016;11(4):e0153267.","journal-title":"PLoS One"},{"issue":"5","key":"321_CR15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/acr.23327","volume":"70","author":"Anita Tollisen","year":"2018","unstructured":"Tollisen A, Selvaag AM, Aulie HA, Lilleby V, Aasland A, Lerdal A, et al. Physical functioning, pain and health-related quality of life in adults with juvenile idiopathic arthritis: a longitudinal 30-year follow-up study. Arthritis Care Res. 2018;70(5):741\u2013749","journal-title":"Arthritis Care & Research"},{"key":"321_CR16","doi-asserted-by":"crossref","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005. p. 404.","DOI":"10.1093\/oso\/9780198529446.001.0001"},{"key":"321_CR17","unstructured":"CADTH. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006."},{"key":"321_CR18","unstructured":"NICE.\u00a0Developing NICE guidelines: the manual; 2014. [Available from:\u00a0 https:\/\/www.nice.org.uk\/process\/pmg20\/chapter\/introduction-and-overview ]."},{"key":"321_CR19","unstructured":"CADTH. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017."},{"issue":"2","key":"321_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1\u20135.","journal-title":"Value Health"},{"key":"321_CR21","volume-title":"Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg","author":"Zorginstituut Nederland","year":"2016","unstructured":"Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. 2016."},{"issue":"6","key":"321_CR22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jval.2017.06.011","volume":"21","author":"JC Thorn","year":"2018","unstructured":"Thorn JC, Brookes ST, Ridyard C, Riley R, Hughes DA, Wordsworth S, et al. Core items for a standardized resource use measure: expert Delphi consensus survey. Value Health. 2018;21(6):640\u20139.","journal-title":"Value Health"},{"issue":"10","key":"321_CR23","doi-asserted-by":"publisher","first-page":"e2759","DOI":"10.1097\/MD.0000000000002759","volume":"95","author":"LE Leggett","year":"2016","unstructured":"Leggett LE, Khadaroo RG, Holroyd-Leduc J, Lorenzetti DL, Hanson H, Wagg A, et al. Measuring resource utilization: a systematic review of validated self-reported questionnaires. Medicine (Baltimore). 2016;95(10):e2759.","journal-title":"Medicine (Baltimore)"},{"key":"321_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jclinepi.2015.09.019","volume":"74","author":"CY Noben","year":"2016","unstructured":"Noben CY, de Rijk A, Nijhuis F, Kottner J, Evers S. The exchangeability of self-reports and administrative health care resource use measurements: assessement of the methodological reporting quality. J Clin Epidemiol. 2016;74:93\u2013106 e2.","journal-title":"J Clin Epidemiol"},{"key":"321_CR25","unstructured":"DIRUM. Database of Instruments for Resource Use Measurement [Available from: http:\/\/www.dirum.org\/ ]."},{"issue":"1","key":"321_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O'malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332.","journal-title":"Int J Soc Res Methodol"},{"key":"321_CR27","unstructured":"Mays N, Roberts E, Popay J. Synthesising research evidence. In: N. Fulop, P. Allen, A. Clarke, N. Black, editors. Methods for studying the delivery and organisation of health services. London: Routledge; 2001."},{"key":"321_CR28","unstructured":"CADTH. Strings attached: CADTH database search filters [internet]. Ottawa: CADTH; 2016. [cited 2017 November 17]. https:\/\/www.cadth.ca\/resources\/finding-evidence\/strings-attached-cadths-database-search-filters ."},{"issue":"7","key":"321_CR29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","volume":"119","author":"A Angelis","year":"2015","unstructured":"Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119(7):964\u201379.","journal-title":"Health Policy"},{"issue":"5","key":"321_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11926-015-0508-1","volume":"17","author":"W Gidman","year":"2015","unstructured":"Gidman W, Meacock R, Symmons D. The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication. Curr Rheumatol Rep. 2015;17(5):31.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"321_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.berh.2005.11.004","volume":"20","author":"K Minden","year":"2006","unstructured":"Minden K. What are the costs of childhood-onset rheumatic disease? Best Pract Res Clin Rheumatol. 2006;20(2):223\u201340.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"34","key":"321_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20340","volume":"20","author":"J Shepherd","year":"2016","unstructured":"Shepherd J, Cooper K, Harris P, Picot J, Rose M. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1\u2013222.","journal-title":"Health Technol Assess"},{"issue":"6","key":"321_CR33","first-page":"952","volume":"19","author":"SH Allaire","year":"1992","unstructured":"Allaire SH, DeNardo BS, Szer IS, Meenan RF, Schaller JG. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol. 1992;19(6):952\u20135.","journal-title":"J Rheumatol"},{"key":"321_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12891-016-1129-1","volume":"17","author":"A Angelis","year":"2016","unstructured":"Angelis A, Kanavos P, Lopez-Bastida J, Linertova R, Serrano-Aguilar P, B-RR N. Socioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom. BMC Musculoskelet Disord. 2016;17:321.","journal-title":"BMC Musculoskelet Disord"},{"issue":"4","key":"321_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ctim.2009.03.003","volume":"17","author":"K Toupin-April","year":"2009","unstructured":"Toupin-April K, Feldman DE, Zunzunegui MV, Descarreaux M, Malleson P, Duffy CM. Longitudinal analysis of complementary and alternative health care use in children with juvenile idiopathic arthritis. Complement Ther Med. 2009;17(4):208\u201315.","journal-title":"Complement Ther Med"},{"issue":"1","key":"321_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.22463","volume":"57","author":"S Bernatsky","year":"2007","unstructured":"Bernatsky S, Duffy C, Malleson P, Feldman DE, St Pierre Y, Clarke AE. Economic impact of juvenile idiopathic arthritis. Arthritis Rheum. 2007;57(1):44\u20138.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"321_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1546-0096-11-24","volume":"11","author":"A Ens","year":"2013","unstructured":"Ens A, Lang B, Ramsey S, Stringer E, Huber AM. The financial burden of juvenile idiopathic arthritis: a Nova Scotia experience. Pediatr Rheumatol Online J. 2013;11(1):24.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"39","key":"321_CR38","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta9390","volume":"9","author":"H Epps","year":"2005","unstructured":"Epps H, Ginnelly L, Utley M, Southwood T, Gallivan S, Sculpher M, et al. Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. Health Technol Assess. 2005;9(39):iii\u2013v ix-x, 1-59.","journal-title":"Health Technol Assess"},{"issue":"11","key":"321_CR39","first-page":"2286","volume":"31","author":"J Haapasaari","year":"2004","unstructured":"Haapasaari J, Kautiainen HJ, Isomaki HA, Hakala M. Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2286\u20139.","journal-title":"J Rheumatol"},{"issue":"12","key":"321_CR40","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/acr.22903","volume":"68","author":"NJ Luca","year":"2016","unstructured":"Luca NJ, Burnett HF, Ungar WJ, Moretti ME, Beukelman T, Feldman BM, et al. Cost-effectiveness analysis of first-line treatment with biologic agents in Polyarticular juvenile idiopathic arthritis. Arthritis Care Res. 2016;68(12):1803\u201311.","journal-title":"Arthritis Care Res"},{"issue":"7","key":"321_CR41","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/ard.2003.008516","volume":"63","author":"K Minden","year":"2004","unstructured":"Minden K, Niewerth M, Listing J, Biedermann T, Schontube M, Zink A. Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(7):836\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"321_CR42","first-page":"863","volume":"27","author":"K Minden","year":"2009","unstructured":"Minden K, Niewerth M, Listing J, Mobius D, Thon A, Ganser G, et al. The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database. Clin Exp Rheumatol. 2009;27(5):863\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"321_CR43","first-page":"878","volume":"29","author":"H Pohjankoski","year":"2011","unstructured":"Pohjankoski H, Latva K, Kautiainen H, Saila H, Klaukka T, Virta L, et al. First-year purchases of disease-modifying drugs of incident patients with chronic juvenile arthritis in Finland. Clin Exp Rheumatol. 2011;29(5):878\u201381.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"321_CR44","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/rheumatology\/keq432","volume":"50","author":"FH Prince","year":"2011","unstructured":"Prince FH, de Bekker-Grob EW, Twilt M, van Rossum MA, Hoppenreijs EP, ten Cate R, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch arthritis and biologicals in children register. Rheumatology (Oxford). 2011;50(6):1131\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"321_CR45","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/rheumatology\/keu414","volume":"54","author":"RS Rasu","year":"2015","unstructured":"Rasu RS, Cline SK, Shaw JW, Hayes O, Bawa WA, Cifaldi MA. Impact of JIA on parents\u2019 work absences. Rheumatology. 2015;54(7):1177\u201385.","journal-title":"Rheumatology"},{"issue":"2","key":"321_CR46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jadohealth.2012.01.003","volume":"51","author":"EM Seburg","year":"2012","unstructured":"Seburg EM, Horvath KJ, Garwick AW, McMorris BJ, Vehe RK, Scal P. Complementary and alternative medicine use among youth with juvenile arthritis: are youth using CAM, but not talking about it? J Adolesc Health. 2012;51(2):200\u20132.","journal-title":"J Adolesc Health"},{"issue":"3","key":"321_CR47","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta12030","volume":"12","author":"J Thornton","year":"2008","unstructured":"Thornton J, Ashcroft D, O'Neill T, Elliott R, Adams J, Roberts C, et al. A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management. Health Technol Assess. 2008;12(3):iii\u2013x xi-xiv, 1-208.","journal-title":"Health Technol Assess"},{"issue":"7","key":"321_CR48","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/rheumatology\/ken039","volume":"47","author":"J Thornton","year":"2008","unstructured":"Thornton J, Lunt M, Ashcroft DM, Baildam E, Foster H, Davidson J, et al. Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis. Rheumatology (Oxford). 2008;47(7):985\u201390.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"321_CR49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/acr.20337","volume":"63","author":"WJ Ungar","year":"2011","unstructured":"Ungar WJ, Costa V, Hancock-Howard R, Feldman BM, Laxer RM. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care Res. 2011;63(1):111\u20139.","journal-title":"Arthritis Care Res"},{"key":"321_CR50","unstructured":"Shenoi S, Horneff G, Cidon M, Ramanan AV, Kimura Y, Quartier P, et al. The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. Clin Exp Rheumatol. 2018;36(5):920\u2013928"},{"issue":"6","key":"321_CR51","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jval.2017.06.011","volume":"21","author":"Joanna C. Thorn","year":"2018","unstructured":"Thorn JC, Brookes ST, Ridyard CH, Riley R, Hughes DA, Wordsworth S, et al. Core items for a standardized resource use measure (ISRUM): expert delphi consensus survey. Value in Health 2018;21(6):640\u2013649.","journal-title":"Value in Health"},{"key":"321_CR52","doi-asserted-by":"publisher","first-page":"a1204","DOI":"10.1136\/bmj.a1204","volume":"337","author":"M Drummond","year":"2008","unstructured":"Drummond M, Weatherly H, Ferguson B. Economic evaluation of health interventions. BMJ. 2008;337:a1204.","journal-title":"BMJ"},{"issue":"2","key":"321_CR53","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1017\/S0266462317000526","volume":"33","author":"R Drost","year":"2017","unstructured":"Drost R, van der Putten IM, Ruwaard D, Evers S, Paulus ATG. Conceptualizations of the societal perspective within economic evaluations: a systematic review. Int J Technol Assess Health Care. 2017;33(2):251\u201360.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"321_CR54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1524-4733.2009.00660.x","volume":"13","author":"LP Garrison Jr","year":"2010","unstructured":"Garrison LP Jr, Mansley EC, Abbott TA 3rd, Bresnahan BW, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR drug cost task force report--part II. Value Health. 2010;13(1):8\u201313.","journal-title":"Value Health"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0321-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-019-0321-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0321-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T16:56:50Z","timestamp":1721235410000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-019-0321-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,6]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1186\/s12969-019-0321-x","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,6]]},"assertion":[{"value":"22 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"20"}}